cramer: this biotech stock could be worth over $100 billion on an fda approval
Published 5 years ago • 412K plays • Length 5:19Download video MP4
Download video MP3
Similar videos
-
1:04
an fda approval could be worth over $100 billion to this biotech stock
-
1:22
cramer remix: this could be the hottest biotech stock of the year
-
1:50
jim cramer: there will be push back on biogen's alzheimer's drug price
-
3:45
cramer: biogen's alzheimer's treatment would be 'the biggest drug ever'
-
5:08
palantir has momentum, 'valuation is the concern', says jefferies' brent thill
-
11:17
pfizer ceo albert bourla goes one-on-one with jim cramer
-
3:15
jim cramer looks at investing opportunities in europe
-
3:32
jim cramer on how lilly's alzheimer's drug compares to biogen's
-
2:12
jim cramer on fda resignations connected to the approval of biogen’s alzheimer’s drug
-
3:03
jim cramer: vertex pharma 'dinged' after dem debate, sets up a 'buyable dip'
-
2:41
analyst on what biogen's alzheimer's drug means for the company
-
12:05
jim cramer: investors must consider these two critical factors affecting facebook and apple
-
1:35
cramer's mad dash: dell technologies
-
7:19
how stock exchange and biotech stocks could benefit from an inflation uptick
-
11:19
lightning will never 'strike' an index fund like it did biogen on tuesday, jim cramer says
-
2:36
biotech may be immune to market weakness: technician
-
4:58
jim cramer: investors should wait to buy winning industrial stocks such as caterpillar
-
4:02
lightning round: i can't recommend ford, says jim cramer
-
3:15
jim cramer: life won't be back to normal until there's a covid-19 vaccine
-
5:36
pain & addiction - biodelivery sciences | mad money | cnbc
-
10:17
we're expecting to get at least six drug approvals from the fda in 2020: glaxosmithkline ceo